French study on outcomes in HR+/HER2- early breast cancer patients with Oncotype DX
Part of Cancer, Skin clinical trials.
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have early-stage breast cancer that can be removed with surgery
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative
- You have had an Oncotype DX test on your tumor sample
- You have not had chemotherapy or hormone therapy before surgery
- You do not have cancer in more than 4 lymph nodes, distant spread, or another cancer in the past 10 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This trial studies whether younger, premenopausal women with early-stage, hormone-sensitive breast cancer can safely use hormone therapy alone after surgery, based on their tumor's gene activity score (Oncotype DX). It aims to find the best treatment approach based on your cancer's biology.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
This study checks whether a blood test that looks for “tumor DNA” (circulating tumor DNA) can help evaluate how well neoadjuvant chemotherapy worked for breast cancer. It may help doctors better understand treatment response after surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.